ONE Innovation Labs

ONE Innovation Labs is a clinical-stage pharmaceutical company dedicated to developing advanced topical therapies for dermatological and inflammatory conditions. The company utilizes a proprietary delivery platform designed to optimize the penetration and efficacy of cannabinoid-based compounds through the skin. Its lead program, ONE-101, is a topical cannabinoid formulation currently being evaluated in clinical trials for the treatment of atopic dermatitis and associated pruritus. By targeting the endocannabinoid system, the company aims to provide effective, non-steroidal alternatives for patients suffering from chronic skin diseases. ONE Innovation Labs is headquartered in Miami, Florida, and focuses on bridging the gap between cannabinoid science and traditional pharmaceutical standards.